AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39535661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cipaglucosidase alfa plus miglustat (cipa+mig)
Number of subjects: 100
Study 39535661 — intervention group
Group type: COMPARATOR
Intervention: Alglucosidase alfa plus placebo (alg+pbo)
Number of subjects: 100
Study 39535683 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 1615
Study 39535685 — intervention group
Group type: EXPERIMENTAL
Intervention: IXE/IXE (continuous treatment)
Number of subjects: 289
Study 39535685 — intervention group
Group type: COMPARATOR
Intervention: IXE/PBO (interrupted treatment)
Number of subjects: 289
Study 39535685 — intervention group
Group type: EXPERIMENTAL
Intervention: IXE/PBO + IXEQ4W (retreatment after relapse)
Number of subjects: 289
Study 39535685 — intervention group
Group type: EXPERIMENTAL
Intervention: IXE (continuous treatment)
Number of subjects: 289
Study 39535768 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom screening with symptom feedback and management care pathways
Number of subjects: 445
Study 39535768 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 445
Study 39535812 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom screening with SSPedi (daily for 5 days)
Number of subjects: 345
Study 39535812 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom screening with SSPedi
Number of subjects: 345
Study 39535812 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 345
Study 39535868 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39535875 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurology-based collaborative care
Number of subjects: 60
Study 39535875 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 39536019 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based active tDCS (HB-a-tDCS) on the left dorsolateral prefrontal cortex (l-DLPFC)
Number of subjects: 48
Study 39536019 — intervention group
Group type: COMPARATOR
Intervention: Home-based sham tDCS (HB-s-tDCS) on the primary motor cortex (M1)
Number of subjects: 48
Study 39536026 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal stress reduction and lifestyle modification program
Number of subjects: 19
Study 39536238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 2539
Study 39536238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 2539
Study 39536238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 2539
Study 39536238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2539
Study 39536238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (all doses combined)
Number of subjects: 2539
Study 39536246 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplements
Number of subjects: 48
Study 39536246 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antioxidant supplements)
Number of subjects: 48
Study 39536397 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific formula (soy-protein-based, high-monounsaturated-fatty-acid, multi-fiber) as milk replacement for breakfast and an extra meal after dinner.
Number of subjects: 112
Study 39536397 — intervention group
Group type: COMPARATOR
Intervention: Control group (individualized dietary counseling only).
Number of subjects: 112
Study 39536433 — intervention group
Group type: EXPERIMENTAL
Intervention: CDK 4/6 inhibitors (CDK 4-6i)
Number of subjects: 701
Study 39536433 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine sensitive subgroup
Number of subjects: 701
Study 39536433 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary endocrine resistant subgroup
Number of subjects: 701
Study 39536433 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary endocrine resistant subset
Number of subjects: 701
Study 39536433 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (second-line treatment)
Number of subjects: 701
Study 39536433 — intervention group
Group type: COMPARATOR
Intervention: Taxane-based chemotherapy (second-line treatment)
Number of subjects: 701
Study 39536433 — intervention group
Group type: COMPARATOR
Intervention: Everolimus plus exemestane (second-line treatment)
Number of subjects: 701
Study 39536433 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant (second-line treatment)
Number of subjects: 701
Study 39536433 — intervention group
Group type: COMPARATOR
Intervention: Second-line treatments (overall)
Number of subjects: 701
Study 39536455 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26/protein preF RSV vaccine
Number of subjects: 1118
Study 39536477 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-antigen HBV vaccine (3-A-HBV)
Number of subjects: 0
Study 39536477 — intervention group
Group type: COMPARATOR
Intervention: 1-antigen HBV vaccine (1-A-HBV)
Number of subjects: 0
Study 39536691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 39536751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus platinum-based chemotherapy
Number of subjects: 15
Study 39536780 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFES and Sync RF+ treatment (single 20-min treatment on the submental area)
Number of subjects: 8
Study 39536780 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 8
Study 39536846 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding THV
Number of subjects: 759
Study 39536846 — intervention group
Group type: COMPARATOR
Intervention: Balloon-expandable THV
Number of subjects: 759
Study 39536847 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy in patients with nonelevated hsCRP and noncarrier of CYP2C19 LoFA
Number of subjects: 2801
Study 39536847 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone in patients with nonelevated hsCRP and noncarrier of CYP2C19 LoFA
Number of subjects: 2801
Study 39536847 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual/single antiplatelet therapy in patients with elevated hsCRP
Number of subjects: 2801
Study 39536847 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding events
Number of subjects: 2801
Study 39536860 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiered parenting programs (universal, targeted/universal, secondary/tertiary, tertiary)
Number of subjects: 878
Study 39537191 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided de-escalation strategy (switching from ticagrelor/prasugrel to clopidogrel)
Number of subjects: 1000
Study 39537191 — intervention group
Group type: COMPARATOR
Intervention: Standard dual antiplatelet therapy (DAPT; aspirin plus ticagrelor/prasugrel)
Number of subjects: 1000
Study 39537385 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-free group (both GC and HCQ withdrawal)
Number of subjects: 333
Study 39537385 — intervention group
Group type: EXPERIMENTAL
Intervention: HCQ group (discontinued GC but maintained HCQ)
Number of subjects: 333
Study 39537385 — intervention group
Group type: COMPARATOR
Intervention: Dual maintenance group (both GC and HCQ continued)
Number of subjects: 333
Study 39537438 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided SBRT
Number of subjects: 100
Study 39537438 — intervention group
Group type: COMPARATOR
Intervention: CT-guided SBRT
Number of subjects: 100
Study 39537648 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 25
Study 39537876 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic interventions
Number of subjects: 148
Study 39537876 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and exercise programs
Number of subjects: 148
Study 39537876 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced training for palliative care
Number of subjects: 148
Study 39537876 — intervention group
Group type: EXPERIMENTAL
Intervention: CRF guidelines awareness
Number of subjects: 148
Study 39537876 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical training improvements
Number of subjects: 148
Study 39537877 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-symptomatic scintigraphic imaging cascade screening
Number of subjects: 100
Study 39537976 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue
Number of subjects: 1065
Study 39538001 — intervention group
Group type: EXPERIMENTAL
Intervention: Avacincaptad pegol (ACP) 2 mg
Number of subjects: 0
Study 39538001 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 0
Study 39538073 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized implementation evaluation of EBIs
Number of subjects: 31
Study 39538073 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of policy makers and establishment of psychosocial care in insurance systems
Number of subjects: 31
Study 39538073 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharing evidence to increase awareness
Number of subjects: 31
Study 39538139 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication (various classes including thiazide diuretics, ACE inhibitors, ARBs, calcium channel blockers)
Number of subjects: 311
Study 39538139 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based antihypertensive therapy
Number of subjects: 311
Study 39538176 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib 200 mg orally once daily
Number of subjects: 321
Study 39538192 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded CDS-triggering system offering kidney-specific advice
Number of subjects: 66
Study 39538192 — intervention group
Group type: COMPARATOR
Intervention: Current CDS-triggering system
Number of subjects: 66
Study 39538216 — intervention group
Group type: EXPERIMENTAL
Intervention: Shen-based Qigong Exercise (SBQE)
Number of subjects: 40
Study 39538216 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 39538216 — intervention group
Group type: COMPARATOR
Intervention: SBQE vs Control
Number of subjects: 40
Study 39538234 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly (AOM)
Number of subjects: 109
Study 39538259 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-fraction regimen (9 Gy per fraction)
Number of subjects: 162
Study 39538259 — intervention group
Group type: COMPARATOR
Intervention: 5-fraction regimen (7 Gy per fraction)
Number of subjects: 162
Study 39538278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic dissection
Number of subjects: 300
Study 39538278 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery dissection
Number of subjects: 300
Study 39538331 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoantigen DNA vaccine administered via electroporation, three doses encoding an average of 11 neoantigens per patient (range 4-20).
Number of subjects: 18
Study 39538331 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoantigen DNA vaccine
Number of subjects: 18
Study 39539144 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazavirin (TZV) 250 mg capsules three-times daily for 7 days
Number of subjects: 2
Study 39539144 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir 75 mg capsules twice per day for 7 days
Number of subjects: 2
Study 39539489 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endoscopy (within 12 hours after admission)
Number of subjects: 368
Study 39539489 — intervention group
Group type: COMPARATOR
Intervention: Delayed endoscopy (within 12-24 hours after admission)
Number of subjects: 368
Study 39539491 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback augmented mindfulness training (NAMT)
Number of subjects: 31
Study 39539565 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation therapy
Number of subjects: 116
Study 39539565 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 116
Study 39539569 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully immersive virtual reality cognitive training (fi-VRCT)
Number of subjects: 52
Study 39539569 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study 39539664 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant monotherapy
Number of subjects: 400
Study 39539664 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy with anticoagulants and antiplatelet agents
Number of subjects: 400
Study 39539687 — intervention group
Group type: EXPERIMENTAL
Intervention: OSTRC-H2-SLO (translated version of the OSTRC-H2)
Number of subjects: 188
Study 39539687 — intervention group
Group type: EXPERIMENTAL
Intervention: OSTRC-H2-SLO
Number of subjects: 188
Study 39540041 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological model-based decision support system (DSS) advice
Number of subjects: 95
Study 39540041 — intervention group
Group type: COMPARATOR
Intervention: Standard care without DSS advice
Number of subjects: 95
Study 39540187 — intervention group
Group type: EXPERIMENTAL
Intervention: MIND + SOUL brain healthy diet intervention
Number of subjects: 29
Study 39540275 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular unipolar voltage mapping
Number of subjects: 29
Study 39540300 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with prior preeclampsia
Number of subjects: 679
Study 39540300 — intervention group
Group type: COMPARATOR
Intervention: Women from the general population (controls)
Number of subjects: 679
Study 39540322 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 3 months
Number of subjects: 0
Study 39540322 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 12 months
Number of subjects: 0
Study 39540459 — intervention group
Group type: EXPERIMENTAL
Intervention: My Grief app (based on cognitive-behavioural therapy)
Number of subjects: 248
Study 39540459 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no access to the My Grief app)
Number of subjects: 248
Study 39540661 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (37.5 mg/day on days 1-14, 25 mg/day afterward) plus nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 40
Study 39540661 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib plus nivolumab
Number of subjects: 40
Study 39540734 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate 10 mg/kg daily (maximum 372 mg; equivalent to 5.4 mg/kg or 200 mg isavuconazole) for up to 84 days (IA) or 180 days (IM)
Number of subjects: 31
Study 39540734 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate 10 mg/kg daily
Number of subjects: 31
Study 39540734 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated doses of 15 mg/kg
Number of subjects: 31
Study 39540734 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 31
Study 39540799 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF starting at gestational week 16 with HBV vaccinations for the infant
Number of subjects: 280
Study 39540799 — intervention group
Group type: COMPARATOR
Intervention: Standard care: TDF starting at gestational week 28 with HBV vaccinations and HBIG administered to the infant
Number of subjects: 280
Study 39540820 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-QCPA (HeartFlow)
Number of subjects: 33
Study 39540820 — intervention group
Group type: COMPARATOR
Intervention: IVUS
Number of subjects: 33
Study 39540934 — intervention group
Group type: EXPERIMENTAL
Intervention: safinamide 100 mg/day after 2 weeks of 50 mg/day
Number of subjects: 199
Study 39541094 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 135
Study 39541094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 39541169 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg daily for 16 weeks
Number of subjects: 12
Study 39541202 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab plus etoposide and platinum-based chemotherapy (EP)
Number of subjects: 442
Study 39541202 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus etoposide and platinum-based chemotherapy (EP)
Number of subjects: 442
Study 39541340 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health intervention (mHealth) in addition to existing healthcare practices
Number of subjects: 764
Study 39541340 — intervention group
Group type: COMPARATOR
Intervention: Control group adhering to current healthcare practices
Number of subjects: 764
Study 39541340 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health intervention (mHealth)
Number of subjects: 764
Study 39541340 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a live newborn
Number of subjects: 764
Study 39541340 — intervention group
Group type: EXPERIMENTAL
Intervention: Parity
Number of subjects: 764
Study 39541340 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous experience with contraceptive initiation
Number of subjects: 764
Study 39541363 — intervention group
Group type: EXPERIMENTAL
Intervention: Training workshop + hands-on sessions + smoker referral competition + award presentation ceremony
Number of subjects: 184
Study 39541363 — intervention group
Group type: COMPARATOR
Intervention: 3-hour training workshop (control group)
Number of subjects: 184
Study 39541377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor analysis
Number of subjects: 231
Study 39541377 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive SDHA and SDHB staining combined with negative CA9 labeling
Number of subjects: 231
Study 39541377 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma succinate levels above 4.94µM
Number of subjects: 231
Study 39541377 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating miR-483-5p
Number of subjects: 231
Study 39541377 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum of dinucleotide methylation rate of TERT promoter CpGs above 42%
Number of subjects: 231
Study 39541377 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker combinations
Number of subjects: 231
Study 39541377 — intervention group
Group type: EXPERIMENTAL
Intervention: Combining biomarkers with clinical data
Number of subjects: 231
Study 39541403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin treatment
Number of subjects: 154
Study 39541403 — intervention group
Group type: COMPARATOR
Intervention: Control group (plasma)
Number of subjects: 154
Study 39541403 — intervention group
Group type: COMPARATOR
Intervention: Control group (urine)
Number of subjects: 154
Study 39541522 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0
Study 39541537 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-well potential model (DWPM)
Number of subjects: 0
Study 39541537 — intervention group
Group type: EXPERIMENTAL
Intervention: DWPM
Number of subjects: 0
Study 39541551 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic intracerebral hemorrhage (sICH) defined by SITS-MOST criteria
Number of subjects: 4370
Study 39541551 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic intracerebral hemorrhage (aICH) defined by SITS-MOST criteria
Number of subjects: 4370
Study 39541755 — intervention group
Group type: EXPERIMENTAL
Intervention: L test
Number of subjects: 34
Study 39541838 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality intervention (watching a video with virtual reality glasses)
Number of subjects: 82
Study 39541838 — intervention group
Group type: COMPARATOR
Intervention: Control group (no virtual reality intervention)
Number of subjects: 82
Study 39541993 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatrician-led multidisciplinary comprehensive geriatric assessment (CGA)
Number of subjects: 228
Study 39541993 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 228
Study 39541993 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatrician-led multidisciplinary CGA
Number of subjects: 228
Study 39542091 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath Mac video laryngoscope
Number of subjects: 2600
Study 39542091 — intervention group
Group type: COMPARATOR
Intervention: Standard Macintosh laryngoscope
Number of subjects: 2600
Study 39542133 — intervention group
Group type: EXPERIMENTAL
Intervention: Group videoconference intervention (VCI) + standard of care
Number of subjects: 0
Study 39542133 — intervention group
Group type: COMPARATOR
Intervention: Attention control (AC) + standard of care
Number of subjects: 0
Study 39542219 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive disorders of pregnancy (HDP)
Number of subjects: 954
Study 39542219 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-for-gestational-age (SGA) infants
Number of subjects: 954
Study 39542469 — intervention group
Group type: EXPERIMENTAL
Intervention: Bankart repair + remplissage
Number of subjects: 114
Study 39542469 — intervention group
Group type: COMPARATOR
Intervention: Latarjet procedure
Number of subjects: 114
Study 39542473 — intervention group
Group type: EXPERIMENTAL
Intervention: NTDT-PRO T/W domain
Number of subjects: 145
Study 39542473 — intervention group
Group type: EXPERIMENTAL
Intervention: NTDT-PRO SoB domain
Number of subjects: 145
Study 39542473 — intervention group
Group type: COMPARATOR
Intervention: T/W domain
Number of subjects: 145
Study 39542473 — intervention group
Group type: COMPARATOR
Intervention: SoB domain
Number of subjects: 145
Study 39542488 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with hypertension (HTN)
Number of subjects: 314
Study 39542488 — intervention group
Group type: COMPARATOR
Intervention: Men with hypertension (HTN)
Number of subjects: 314
Study 39542488 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with diabetes
Number of subjects: 314
Study 39542488 — intervention group
Group type: COMPARATOR
Intervention: Men with diabetes
Number of subjects: 314
Study 39542488 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who are tobacco users
Number of subjects: 314
Study 39542488 — intervention group
Group type: COMPARATOR
Intervention: Men who are tobacco users
Number of subjects: 314
Study 39542488 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who are smokers
Number of subjects: 314
Study 39542488 — intervention group
Group type: COMPARATOR
Intervention: Men who are smokers
Number of subjects: 314
Study 39542488 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with BMI ≥30 kg/m²
Number of subjects: 314
Study 39542488 — intervention group
Group type: COMPARATOR
Intervention: Men with BMI ≥30 kg/m²
Number of subjects: 314